Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Angiopoietin 1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Angiopoietin 1. Displaying page 1 of 1.
    EudraCT Number: 2020-002796-35 Sponsor Protocol Number: C4491011 Start Date*: 2021-01-07
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participan...
    Medical condition: dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004003-23 Sponsor Protocol Number: ISIS703802 Start Date*: 2016-09-28
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S...
    Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10054380 Familial hypercholesterolemia LLT
    19.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    19.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001105-13 Sponsor Protocol Number: STREAM Start Date*: 2015-06-19
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, single-arm, two-stage, phase 2 study.
    Medical condition: patients with RAS-mutant advanced colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10038029 Rectal adenocarcinoma stage IV LLT
    21.0 100000004864 10001172 Adenocarcinoma of colon stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000437-13 Sponsor Protocol Number: R1500-HTG-20118 Start Date*: 2022-01-07
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
    Medical condition: Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020869 Hypertriglyceridaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002190-33 Sponsor Protocol Number: B1131004 Start Date*: 2012-02-02
    Sponsor Name:PFIZER, S.L.U.
    Full Title: A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA
    Medical condition: METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) CZ (Completed) DE (Prematurely Ended) GB (Completed) AT (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001508-31 Sponsor Protocol Number: R1500-CL-1643 Start Date*: 2017-11-20
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally T...
    Medical condition: Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) NO (Completed) SE (Completed) DK (Completed) PL (Completed) AT (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:54:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA